Business Description
ISIN : US40637H1095
Share Class Description:
HALO: Ordinary SharesTotal Employee Number:
423Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.11 | |||||
Equity-to-Asset | 0.06 | |||||
Debt-to-Equity | 14.96 | |||||
Debt-to-EBITDA | 2.99 | |||||
Interest Coverage | 45.84 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.81 | |||||
Beneish M-Score | -2.09 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 33.9 | |||||
3-Year EBITDA Growth Rate | 27.3 | |||||
3-Year EPS without NRI Growth Rate | 23.4 | |||||
3-Year FCF Growth Rate | 19.8 | |||||
3-Year Book Growth Rate | -30.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 40.83 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 16.73 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.2 | |||||
9-Day RSI | 61.5 | |||||
14-Day RSI | 66.37 | |||||
3-1 Month Momentum % | 45.79 | |||||
6-1 Month Momentum % | 53.07 | |||||
12-1 Month Momentum % | 35.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.71 | |||||
Quick Ratio | 2.31 | |||||
Cash Ratio | 0.67 | |||||
Days Inventory | 208.79 | |||||
Days Sales Outstanding | 89.43 | |||||
Days Payable | 23.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 4.5 | |||||
Shareholder Yield % | -3.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.42 | |||||
Operating Margin % | 55.95 | |||||
Net Margin % | 24.86 | |||||
EBITDA Margin % | 43.18 | |||||
FCF Margin % | 31.16 | |||||
OCF Margin % | 49.2 | |||||
ROE % | 165.62 | |||||
ROA % | 17.16 | |||||
ROIC % | 34.41 | |||||
3-Year ROIIC % | 38.79 | |||||
ROC (Joel Greenblatt) % | 102.15 | |||||
ROCE % | 29.61 | |||||
Years of Profitability over Past 10-Year | 7 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 32.14 | |||||
Forward PE Ratio | 10.16 | |||||
PE Ratio without NRI | 23.18 | |||||
Shiller PE Ratio | 66.06 | |||||
Price-to-Owner-Earnings | 38.23 | |||||
PEG Ratio | 0.64 | |||||
PS Ratio | 7.86 | |||||
PB Ratio | 85.46 | |||||
Price-to-Free-Cash-Flow | 25.37 | |||||
Price-to-Operating-Cash-Flow | 16.05 | |||||
EV-to-EBIT | 23.42 | |||||
EV-to-EBITDA | 19.68 | |||||
EV-to-Forward-EBITDA | 9.92 | |||||
EV-to-Revenue | 8.5 | |||||
EV-to-Forward-Revenue | 6.71 | |||||
EV-to-FCF | 27.27 | |||||
Price-to-GF-Value | 1.09 | |||||
Price-to-Projected-FCF | 2.44 | |||||
Price-to-Median-PS-Value | 0.74 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.93 | |||||
Earnings Yield (Greenblatt) % | 4.27 | |||||
FCF Yield % | 4.24 | |||||
Forward Rate of Return (Yacktman) % | 22.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HALO
Peter Lynch Chart
Performance
Annualized Return %
Total Annual Return %
Halozyme Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,663.738 | ||
| EPS (TTM) ($) | 3.35 | ||
| Beta | 0.7182 | ||
| 3-Year Sharpe Ratio | 0.86 | ||
| 3-Year Sortino Ratio | 1.78 | ||
| Volatility % | 38.93 | ||
| 14-Day RSI | 66.37 | ||
| 14-Day ATR ($) | 2.955261 | ||
| 20-Day SMA ($) | 106.204 | ||
| 12-1 Month Momentum % | 35.95 | ||
| 52-Week Range ($) | 61.225 - 111.15 | ||
| Shares Outstanding (Mil) | 113.5 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Halozyme Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Halozyme Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-17 16:30 | In 162 days | ||
| Annual report for 2026 | 2027-02-17 | In 161 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-17 | In 161 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-03 16:30 | In 56 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 55 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-16 10:00 | In 8 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-15 07:45 | In 7 days | ||
| Wells Fargo 21st Annual Healthcare Conference | 2026-09-09 15:45 | In 1 day | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 83.59 (-0.36%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 83.59 (-0.36%) |
Halozyme Therapeutics Inc Frequently Asked Questions
Guru Commentaries on NAS:HALO
During the quarter, we bought shares in Halozyme Therapeutics, Inc. (Nasdaq: HALO). HALO licenses a technology, ENHANZE®, that allows large pharmaceutical companies to replace hours on an IV drip for a quick shot under the skin. The technology works by injecting an enzyme that temporarily clears a natural gel-like barrier under the skin, letting a large volume of drug spread and absorb fast enough to replace the drip. We built the position at a meaningful discount to what we think the business is worth, and only about half of that value depends on the distant future, a healthier mix than is typical this early in building out a royalty business.
Halozyme Therapeutics, Inc. is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme enables the subcutaneous delivery of biologics and fluids, transforming hours-long intravenous infusions into quick injections delivered in minutes. The technology reduces treatment burden for patients and alleviates capacity constraints for healthcare providers. Halozyme reported a strong quarter, with royalty revenues up 65% and continued uptake of its drugs, along with expanding use-case indications from its pharmaceutical partners. Management raised full-year guidance for both revenues and earnings, which was well-received by investors.
Halozyme Therapeutics, Inc. is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme enables the subcutaneous delivery of biologics and fluids, transforming hours-long intravenous (IV) infusions into quick injections that can be delivered in just minutes. By doing so, ENHANZE can significantly reduce the treatment burden for patients and ease capacity constraints for healthcare providers. While shares declined due to potential changes in Medicare classification, we believe ENHANZE continues to offer meaningful advantages, making it an important innovation in drug delivery.
Press Release
Articles on Halozyme Therapeutics Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
